US2003013197A1PendingUtilityA1

Helper virus-free AAV production

Priority: Jun 7, 1995Filed: Aug 16, 2002Published: Jan 16, 2003
Est. expiryJun 7, 2015(expired)· nominal 20-yr term from priority
C12N 2710/10343C12N 2750/14143C07K 14/005C12N 2710/10322C12N 2750/14152C12N 7/00C12N 15/86
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for the production of adeno-associated virus stocks and recombinant adeno-associated virus stocks that are substantially free of contaminating helper virus is described. The method utilizes transfection with helper virus vectors to replace the infection with helper virus used in the conventional method.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for producing substantially helper-virus free stocks of recombinant adeno-associated virus comprising: 
 (a) cotransfecting cells permissive for adenovirus-associated virus replication with: 
 i) a recombinant adeno-associated virus vector which is capable of being packaged into infectious AAV virions,  
 ii) a helper AAV vector which provides the AAV-viral functions essential for the replication and packaging of said recombinant adeno-associated virus vector into infectious AAV virions, and  
 iii) a helper virus vector which provides the helper-viral functions essential for a productive adeno-associated virus infection but which cannot itself be packaged into infectious helper virus virions; and,  
   (b) collecting virions produced.    
     
     
         2 . The method of  claim 1  wherein said helper virus vector is an adenovirus vector.  
     
     
         3 . The method of  claim 1  wherein said helper virus vector comprises the large XbaI fragment of adenovirus.  
     
     
         4 . The method of  claim 3  wherein said cells are human 293 cells.  
     
     
         5 . The method of  claim 1  wherein said helper AAV vector is incapable of being packaged into infectious AAV virions.  
     
     
         6 . A method for producing substantially helper-virus free stocks of adeno-associated virus comprising: 
 (a) transfecting cells permissive for adenovirus-associated virus replication with a helper virus vector which provides the helper-viral functions essential for a productive adeno-associated virus infection but which cannot itself be packaged into infectious helper virus virions;    (b) infecting said cells with adeno-associated virus; and    (c) collecting virions produced.    
     
     
         7 . A method for producing substantially helper-virus free stocks of adeno-associated virus comprising: 
 (a) transfecting cells permissive for adenovirus-associated virus replication with a helper virus vector which provides the helper-viral functions essential for a productive adeno-associated virus infection but which cannot itself be packaged into infectious helper virus virions;    (b) transfecting said cells with infectious adeno-associated virus DNA; and    (c) collecting virions produced.    
     
     
         8 . Substantially helper-virus free stocks produced by the method of  claim 1 .  
     
     
         9 . Substantially helper-virus free stocks produced by the method of  claim 6 .  
     
     
         10 . Substantially helper-virus free stocks produced by the method of  claim 7 .  
     
     
         11 . A method for producing substantially helper-virus free stocks of recombinant adeno-associated virus comprising: 
 (a) cotransfecting cells permissive for adenovirus-associated virus replication, wherein said cells comprise an extrachromosomal element comprising a helper virus vector which provides the helper viral functions essential for a productive adeno-associated virus infection, with: 
 i) a recombinant adeno-associated virus vector which is capable of being packaged into infectious AAV virions, and  
 ii) a helper AAV vector which provides the AAV-viral functions essential for the replication and packaging of said recombinant adeno-associated virus vector into infectious AAV virions; and  
   (b) collecting virions produced.    
     
     
         12 . Substantially helper-virus free stocks produced by the method of  claim 11 .  
     
     
         13 . A cell line produced by the method comprising the steps of 
 (a) transfecting cells permissive for adenovirus-associated virus replication with: a helper virus vector which provides the helper-viral functions essential for a productive adeno-associated virus infection but which cannot itself be packaged into infectious helper virus virions; and,    (b) selecting a cell line wherein said helper virus vector is present on an extrachromosomal element.    
     
     
         14 . A cell line produced by the method comprising the steps of 
 (a) transfecting cells permissive for adenovirus-associated virus replication with: a helper virus vector which provides the helper-viral functions essential for a productive adeno-associated virus infection but which cannot itself be packaged into infectious helper virus virions; and,    (b) selecting a cell line wherein said helper virus vector is stably integrated into the chromosomal DNA.

Join the waitlist — get patent alerts

Track US2003013197A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.